<!DOCTYPE html>

<html lang="fa">
<meta content="text/html;charset=utf-8" http-equiv="content-type"/>
<head><title>Female pattern hair loss (androgenetic alopecia in females): Management</title><link href="/z/d/css/bootstrap.min.css" rel="stylesheet"/><link href="/z/d/css/icofont.min.css" rel="stylesheet"/><link href="/z/d/css/classy-nav.min.css" rel="stylesheet"/><link href="/z/d/css/animate.css" rel="stylesheet"/><link href="/z/d/css/owl.carousel.css" rel="stylesheet"/><link href="/z/d/css/magnific-popup.css" rel="stylesheet"/><link href="/z/d/css/owl.theme.default.min.css" rel="stylesheet"/><link href="/z/d/css/style.css" rel="stylesheet"/><link href="/z/d/css/rtl_edited.css" rel="stylesheet"/><link href="/z/d/css/responsive.css" rel="stylesheet"/><link href="https:///uptodate_assets/main.css" rel="stylesheet"/>
<style>

#myUL {
  list-style-type: none;
  padding: 0;
  margin: 0;
}

#myUL li a {
  border: 1px solid #ddd;
  margin-top: -1px; /* Prevent double borders */
  background-color: #f6f6f6;
  padding: 12px;
  text-decoration: none;
  font-size: 16px;
  color: black;
  display: block
}

#myUL li a:hover:not(.header) {
  background-color: #eee;
}

#searchResult {

  list-style-type: none;
  padding: 0;
  padding-right: 20px;
}

#searchResult li a {
  border: .5px solid #ddd;
  margin-top: -1px; /* Prevent double borders */
  background-color: #79bc21;
  padding: 7px;
  text-decoration: none;
  font-size: 14px;
  color: white;
  display: block
}

#searchResult li a:hover:not(.header) {
  background-color: #222;
}


#txtHint   {
  position: absolute;
  text-shadow: none;
  width: 100%;
  margin-top: -15px;
  padding-right: 10px;

  filter: alpha(opacity=95);
  -moz-opacity: 0.95;
  opacity: 1;
  z-index: 200;
}
.countBubl {
  background:#eb0029;
  color:#fff;
  padding:5px;
  margin-top: 50%;

}
.uptodate-area > div:nth-child(1) > div:nth-child(1) > div:nth-child(1) > span:nth-child(1) > img:nth-child(2) {
 width: 55%;
 padding-left: 20px;
}
.uptodate-area > div:nth-child(1) > div:nth-child(1) > div:nth-child(1) > span:nth-child(1) > img:nth-child(3) {
 width: 20%;
}
 #Uptodate_image {
      width: 50%;
  }#uptodate-area {
      /*z-index: 99;*/
  }
#uptodate-area > div:nth-child(1) > div:nth-child(1) > div:nth-child(1) > div:nth-child(2) {
 margin-left: 10px;
 margin-bottom: 6%;
}
@media (max-width: @screen-xs) {
    .countBubl {
        font-size: 4px ;
    }
    #uptodate_version {
        font-size: 4px ;
    }
}

@media (max-width: @screen-sm) {
    .countBubl {
        font-size: 14px ;
    }
}
@media  all and(max-width: 820) {
    #Uptodate_image {
        width: 80% ;
    }#uptodate-area {
        z-index: 99;
    }
}@media  all and (min-width: 820) and(max-width: 88820){
    #Uptodate_image {
        width: 100% !important;
    }
    .countBubl {
        font-size: 4px ;
    }
}
div.col-md-3:nth-child(3) {
 margin-top: 6%;
}

div.col-md-3:nth-child(3) > img:nth-child(1) {
 width: 100%;
 margin-left: 11px;
}

</style>
<style media="screen" type="text/css">
  .goback {
    width: 200px;
    height: 40px;
    line-height: 40px;
    position: fixed;
    display: none;
    font-size: 15px;
    background: #71c0fa;
    z-index: 1000;
    text-align: center;
    color: #ffffff;
    -webkit-border-radius: 1px;
    -moz-border-radius: 1px;
    border-radius: 50px;
    bottom: 3.8%;
    right: 2%;
}
  .buyPackage {
  width: 100px;
  height: 100px;
  line-height: 40px;
  position: fixed;
  display: none;
  font-size: 10px;
  background: #fa759e;
  z-index: 1000;
  text-align: center;
  color: #ffffff;
  -webkit-border-radius: 1px;
  -moz-border-radius: 1px;
  border-radius: 10px;
  top: 150px;
  right: 2%;
  text-align: center;
}
.uptodate-area {
  /*background-image: url(../../assets/img/news-letter-bg.jpg);*/
  background-position: center center;
  background-size: cover;
  background-repeat: no-repeat;
    background-attachment: fixed;
  position: relative;
}
.uptodate-area::before {
  content: '';
  position: absolute;
  left: 0;
  padding-top: 100px;
  width: 100%;
}
#references{
  display: none;
}
</style>
<style>
section.sticky {
  position: sticky;
  top: 0;
  background-color: #fff !important;
  /*z-index: 100;*/
  /*padding-top: 80px;*/

}
.m4inb{
    border: solid !important;
  }

  .newsletter-area::before {
       background: unset !important;
  }
p {
    color: #555;
}
</style>
<meta content="" name="description"/>
<link href="/z/d/img/favicon.png" rel="icon" type="image/png">
</link></head>
<body>
<!-- Start Main Menu Area -->
<br/>
<br/>
<br/>
<br/>
<div class="container">
<div class="row">
</div>
</div>
<section class="teacher-area ptb-10">
<div class="container">
</div>
<section class="course-details-area ptb-60">
<div class="container">
<div class="uptodate2" style="padding:50px 0px 50px 0px;direction: ltr;text-align: left;">
<h1 style="text-align:center">Female pattern hair loss (androgenetic alopecia in females): Management</h1>
<div class="utdArticleSection utdStyle" id="topicContent"><div id="topicTitle">Female pattern hair loss (androgenetic alopecia in females): Management</div> <div class="authorSectionElem"><div class="authorsElementsLeft"><dl id="topicContributors"><dt><span> </span>Author:</dt><dd><a class="contributor contributor_credentials" rel="noopener noreferrer" target="_blank">Amy McMichael, MD</a></dd><dt><span> </span>Section Editor:</dt><dd><a class="contributor contributor_credentials" rel="noopener noreferrer" target="_blank">Maria Hordinsky, MD</a></dd><dt><span> </span>Deputy Editor:</dt><dd><a class="contributor contributor_credentials" rel="noopener noreferrer" target="_blank">Abena O Ofori, MD</a></dd></dl></div><div class="authorsElementsRight"><div id="literatureReviewDate"><div class="litReviewSingleLine"><bdi><span class="emphasis">Literature review current through:</span> Jan 2024.</bdi></div><div class="litReviewSingleLine"><bdi><span class="emphasis">This topic last updated:</span> Dec 21, 2021.</bdi></div></div></div></div><div id="topicWhatsNewContainer"></div><div id="topicText"><p class="headingAnchor" id="H633853598"><span class="h1">INTRODUCTION</span><span class="headingEndMark"> — </span>Female pattern hair loss (FPHL; female pattern alopecia, androgenetic alopecia in females) is a common form of nonscarring hair loss that most frequently occurs in adult females and primarily involves the frontal scalp and vertex of the scalp  (<a class="graphic graphic_picture graphicRef87193 graphicRef87194 graphicRef87195" href="/z/d/graphic/87193.html" rel="external">picture 1A-C</a>). Untreated, FPHL results in a slow, progressive decline in the density of scalp hair but does not typically progress to baldness.</p><p>Hair loss related to FPHL can be distressing, and many patients desire treatment. Topical <a class="drug drug_general" data-topicid="9655" href="/z/d/drug information/9655.html" rel="external">minoxidil</a>; oral antiandrogenic drugs; and other topical, oral, and procedural therapies have been used for FPHL  (<a class="graphic graphic_algorithm graphicRef134317" href="/z/d/graphic/134317.html" rel="external">algorithm 1</a>). Hair transplantation surgery is an option for patients who have inadequate responses to medical therapy.</p><p>The management of FPHL will be reviewed here. The pathogenesis, clinical manifestations, and diagnosis of FPHL; the diagnosis and management of male pattern hair loss (androgenetic alopecia in males); and the general evaluation of patients with hair loss are discussed separately.</p><p class="bulletIndent1"><span class="glyph">●</span>(See  <a class="medical medical_review" href="/z/d/html/15679.html" rel="external">"Female pattern hair loss (androgenetic alopecia in females): Pathogenesis, clinical features, and diagnosis"</a>.)</p><p class="bulletIndent1"><span class="glyph">●</span>(See  <a class="medical medical_review" href="/z/d/html/83783.html" rel="external">"Male pattern hair loss (androgenetic alopecia in males): Pathogenesis, clinical features, and diagnosis"</a>.)</p><p class="bulletIndent1"><span class="glyph">●</span>(See  <a class="medical medical_review" href="/z/d/html/3321.html" rel="external">"Male pattern hair loss (androgenetic alopecia in males): Management"</a>.)</p><p class="bulletIndent1"><span class="glyph">●</span>(See  <a class="medical medical_review" href="/z/d/html/15678.html" rel="external">"Evaluation and diagnosis of hair loss"</a>.)</p><p></p><p class="headingAnchor" id="H732424038"><span class="h1">TREATMENT PRINCIPLES</span><span class="headingEndMark"> — </span>Female pattern hair loss (FPHL) typically progresses over time, resulting in diminishing hair coverage over affected areas of the scalp. The primary goals of treatment are to minimize additional hair loss and to induce regrowth of terminal hairs.</p><p>Responses to treatment vary, ranging from no effect, to improvement limited to the inhibition of further hair loss, to a variable degree of regrowth of hair. A favorable response may be considered cessation of the progression of hair loss and improvement in hair density that is cosmetically satisfactory for the patient. Initiating treatment early, prior to the development of extensive hair loss, is preferred given the potential for incomplete responses.</p><p>Counseling of patients should involve a discussion of the therapeutic options as well as realistic expectations for the duration of treatment and expected outcomes. At least several months of treatment are usually required to achieve initial clinical signs of a response, and effective pharmacologic therapy typically must be continued indefinitely to maintain improvement.</p><p class="headingAnchor" id="H3722692982"><span class="h1">ASSESSING RESPONSE</span><span class="headingEndMark"> — </span>Given that responses to treatment are delayed, periodic follow-up is reasonable. Provided that patients are tolerating treatment well, we typically reassess patients every four to six months.</p><p>The physical examination is the primary method of assessing the response to treatment. Serial photographs are valuable for identifying improvement in hair coverage on the scalp. Use of grading scales, such as the Ludwig or Sinclair scales, may be helpful for documenting baseline severity  (<a class="graphic graphic_figure graphicRef87190" href="/z/d/graphic/87190.html" rel="external">figure 1</a> and <a class="graphic graphic_picture graphicRef87210" href="/z/d/graphic/87210.html" rel="external">picture 2</a>). Additional methods commonly used in clinical studies include measurements of hair density and hair diameter.</p><p class="headingAnchor" id="H3931292852"><span class="h1">INITIAL THERAPY</span><span class="headingEndMark"> — </span>We aim to incorporate topical <a class="drug drug_general" data-topicid="9655" href="/z/d/drug information/9655.html" rel="external">minoxidil</a> in the treatment of all patients for female pattern hair loss (FPHL)  (<a class="graphic graphic_algorithm graphicRef134317" href="/z/d/graphic/134317.html" rel="external">algorithm 1</a>). Compared with other interventions, topical minoxidil has the strongest evidence for efficacy and is generally well tolerated [<a href="#rid1">1,2</a>]. We also typically prescribe an oral antiandrogenic agent (usually <a class="drug drug_general" data-topicid="9943" href="/z/d/drug information/9943.html" rel="external">spironolactone</a>). The addition of an oral antiandrogen is based upon limited data that suggest benefit of oral antiandrogenic therapy. (See <a class="local">'Topical minoxidil'</a> below and <a class="local">'Adjunctive oral therapy'</a> below.)</p><p>Hyperandrogenism and concomitant inflammatory scalp disorders that may contribute to hair loss should be treated. (See <a class="local">'Patients with hyperandrogenism'</a> below and <a class="local">'Patients with concomitant scalp disorders'</a> below.)</p><p class="headingAnchor" id="H633853619"><span class="h2">Topical minoxidil</span><span class="headingEndMark"> — </span>Topical <a class="drug drug_general" data-topicid="9655" href="/z/d/drug information/9655.html" rel="external">minoxidil</a> is available in a variety of formulations. In the United States, minoxidil may be obtained commercially as a 2% solution, 5% solution, or 5% foam:</p><p class="bulletIndent1"><span class="glyph">●</span><strong>Product selection</strong> – All three commercial formulations of <a class="drug drug_general" data-topicid="9655" href="/z/d/drug information/9655.html" rel="external">minoxidil</a> (2% solution, 5% solution, and 5% foam) are effective for FPHL. Historically, many clinicians recommended use of minoxidil 5% solution or foam based upon a perception of greater efficacy than minoxidil 2% solution; however, data to support this assertion are lacking. In a systematic review of randomized trials evaluating interventions for FPHL, none of the four trials that compared minoxidil 2% with minoxidil 5% found a significant difference in efficacy between the two concentrations [<a href="#rid2">2</a>].</p><p></p><p class="bulletIndent1"><a class="drug drug_general" data-topicid="9655" href="/z/d/drug information/9655.html" rel="external">Minoxidil</a> 5% foam offers drug delivery in a vehicle that may be preferred by some patients and is associated with a reduced risk for side effects (eg, scalp pruritus, dandruff, sideburn hypertrichosis) compared with twice-daily application of the 2% solution [<a href="#rid3">3</a>]. In a vehicle-controlled, randomized trial (n = 404), the incidences of scalp irritation and hypertrichosis with once-daily use of minoxidil 5% foam were comparable with vehicle [<a href="#rid4">4</a>].</p><p></p><p class="bulletIndent1"><span class="glyph">●</span><strong>Administration</strong> – <a class="drug drug_general" data-topicid="9655" href="/z/d/drug information/9655.html" rel="external">Minoxidil</a> 2% solution (1 mL) is usually applied twice daily. Minoxidil 5% solution (1 mL) or foam (one-half capful) is usually applied once daily. Patients should be instructed to apply minoxidil to the scalp, not the hair. The patient should massage minoxidil onto the scalp with fingers, and hands should be washed after application. Patients should apply the product at least two hours before bed to allow adequate time for drying. This may help to avoid the inadvertent spread of the solution to other body sites during sleeping.</p><p></p><p class="bulletIndent1">Treatment with <a class="drug drug_general" data-topicid="9655" href="/z/d/drug information/9655.html" rel="external">minoxidil</a> takes at least four months to exhibit a visible effect. We typically assess patients for initial signs of response after six to nine months. Use of the product for at least 12 months prior to concluding inefficacy is recommended [<a href="#rid5">5</a>].</p><p></p><p class="bulletIndent1"><span class="glyph">●</span><strong>Efficacy</strong> – The exact mechanism through which <a class="drug drug_general" data-topicid="9655" href="/z/d/drug information/9655.html" rel="external">minoxidil</a> improves FPHL is not completely understood. It is theorized that the drug may prolong the anagen (growth) phase of hair follicles, shorten the telogen (resting) phase, and induce enlargement of miniaturized follicles, thereby contributing to the conversion of miniaturized hairs to terminal hairs [<a href="#rid6">6</a>]. (See  <a class="medical medical_review" href="/z/d/html/3321.html" rel="external">"Male pattern hair loss (androgenetic alopecia in males): Management"</a>.)</p><p></p><p class="bulletIndent1">The efficacy of topical <a class="drug drug_general" data-topicid="9655" href="/z/d/drug information/9655.html" rel="external">minoxidil</a> for FPHL is supported by a systematic review and meta-analysis of randomized trials that found that patients treated with topical minoxidil (1%, 2%, or 5% formulations) were more likely to report clinically significant hair regrowth than patients in the placebo groups (risk ratio 1.93, 95% CI 1.51-2.47) [<a href="#rid2">2</a>]. In addition, the mean increase in hair counts within treated areas was higher in patients treated with minoxidil than in patients in the placebo groups. A subsequent, randomized trial that compared minoxidil 5% foam with placebo also supports the efficacy of minoxidil [<a href="#rid4">4</a>].</p><p></p><p class="bulletIndent1"><span class="glyph">●</span><strong>Adverse effects</strong> – Shedding of hair commonly occurs during the first two to eight weeks of <a class="drug drug_general" data-topicid="9655" href="/z/d/drug information/9655.html" rel="external">minoxidil</a> treatment [<a href="#rid3">3,5</a>], an event likely due to the release of telogen hairs, as follicles are stimulated to transition from telogen to the anagen phase [<a href="#rid7">7</a>]. Patients should be warned about this side effect to avoid the premature cessation of treatment.</p><p></p><p class="bulletIndent1">Potential local adverse effects of <a class="drug drug_general" data-topicid="9655" href="/z/d/drug information/9655.html" rel="external">minoxidil</a> include scalp pruritus, flaking, and facial hypertrichosis. The low risk for scalp irritation with use of the 5% foam formulation may be related to the absence of propylene glycol, a common contact allergen, in this formulation. Hypertrichosis usually resolves within four months if treatment is discontinued [<a href="#rid5">5</a>]. (See  <a class="medical medical_review" href="/z/d/html/3321.html" rel="external">"Male pattern hair loss (androgenetic alopecia in males): Management"</a>.)</p><p></p><p class="bulletIndent1">Oral <a class="drug drug_general" data-topicid="9655" href="/z/d/drug information/9655.html" rel="external">minoxidil</a> may be an alternative for patients who are unable to tolerate topical minoxidil. (See <a class="local">'Oral minoxidil'</a> below.)</p><p></p><p class="headingAnchor" id="H2000919449"><span class="h2">Adjunctive oral therapy</span><span class="headingEndMark"> — </span>Our initial treatment protocol typically consists of topical <a class="drug drug_general" data-topicid="9655" href="/z/d/drug information/9655.html" rel="external">minoxidil</a> plus an oral antiandrogenic agent for patients who can tolerate oral antiandrogenic therapy  (<a class="graphic graphic_algorithm graphicRef134317" href="/z/d/graphic/134317.html" rel="external">algorithm 1</a>). Androgens are postulated to play a role in FPHL, although the nature and degree of androgen involvement in the pathogenesis of FPHL are unclear. (See  <a class="medical medical_review" href="/z/d/html/15679.html" rel="external">"Female pattern hair loss (androgenetic alopecia in females): Pathogenesis, clinical features, and diagnosis", section on 'Androgens'</a>.)</p><p><a class="drug drug_general" data-topicid="9943" href="/z/d/drug information/9943.html" rel="external">Spironolactone</a> is our preferred antiandrogen based upon data that suggest benefit for FPHL and the extensive experience with this drug for other indications in females (eg, hirsutism, acne, polycystic ovarian syndrome). Alternatives include <a class="drug drug_general" data-topicid="8447" href="/z/d/drug information/8447.html" rel="external">finasteride</a> (a 5-alpha-reductase inhibitor) or <a class="drug drug_general" data-topicid="9295" href="/z/d/drug information/9295.html" rel="external">cyproterone acetate</a>. We tend to use finasteride when patients do not tolerate spironolactone, prefer to avoid spironolactone, or have a poor response to spironolactone. Cyproterone acetate is not available in the United States. Use of all antiandrogenic agents should be avoided in pregnancy. (See <a class="local">'Spironolactone'</a> below and <a class="local">'Finasteride'</a> below and <a class="local">'Cyproterone acetate'</a> below.)</p><p class="headingAnchor" id="H633853661"><span class="h3">Spironolactone</span><span class="headingEndMark"> — </span><a class="drug drug_general" data-topicid="9943" href="/z/d/drug information/9943.html" rel="external">Spironolactone</a> is an aldosterone antagonist that competitively blocks androgen receptors and weakly inhibits androgen synthesis [<a href="#rid8">8,9</a>]:</p><p class="bulletIndent1"><span class="glyph">●</span><strong>Administration</strong> – The typical dose of <a class="drug drug_general" data-topicid="9943" href="/z/d/drug information/9943.html" rel="external">spironolactone</a> utilized for adults with FPHL is 100 to 200 mg per day. Treatment is usually begun at a lower dose (eg, 50 mg per day) to support tolerance of the drug. Provided that patients tolerate the 50 mg dose, we increase the dose to 100 mg per day after two to four weeks.</p><p></p><p class="bulletIndent1"><a class="drug drug_general" data-topicid="9943" href="/z/d/drug information/9943.html" rel="external">Spironolactone</a> should be continued for at least six months prior to assessing its efficacy. For insufficient responses, the daily dose may be increased up to a maximum daily dose of 200 mg.</p><p></p><p class="bulletIndent1"><span class="glyph">●</span><strong>Efficacy</strong> – Data in support of the use of <a class="drug drug_general" data-topicid="9943" href="/z/d/drug information/9943.html" rel="external">spironolactone</a> for FPHL include open-label and retrospective studies, case reports, and case series [<a href="#rid10">10-15</a>]. In a retrospective study of 79 adults with FPHL treated with spironolactone (average dose 100 mg per day, range 25 to 200 mg per day) alone or in combination with topical <a class="drug drug_general" data-topicid="9655" href="/z/d/drug information/9655.html" rel="external">minoxidil</a> or low-level laser therapy (LLLT) for at least six months, all patients improved or maintained their initial Sinclair score  (<a class="graphic graphic_picture graphicRef87210" href="/z/d/graphic/87210.html" rel="external">picture 2</a>) [<a href="#rid16">16</a>].</p><p></p><p class="bulletIndent1">An open-label study did not find a significant difference in efficacy between <a class="drug drug_general" data-topicid="9943" href="/z/d/drug information/9943.html" rel="external">spironolactone</a> and <a class="drug drug_general" data-topicid="9295" href="/z/d/drug information/9295.html" rel="external">cyproterone acetate</a> [<a href="#rid10">10</a>]. In the study, 80 patients with FPHL (ages 12 to 79, most with normal androgen levels) were treated with spironolactone (200 mg per day) or cyproterone acetate (50 mg per day for postmenopausal patients and 100 mg per day for 10 days per month in conjunction with an oral contraceptive pill for premenopausal patients). All patients were treated for at least 12 months, and the average duration of treatment was 16 months. Overall, 44 percent of patients had regrowth, 44 percent had no change in hair density, and 12 percent had continued hair loss.</p><p></p><p class="bulletIndent1"><span class="glyph">●</span><strong>Adverse effects</strong> – Potential side effects of <a class="drug drug_general" data-topicid="9943" href="/z/d/drug information/9943.html" rel="external">spironolactone</a> include headache, decreased libido, menstrual irregularities, orthostatic hypotension, fatigue, and hyperkalemia. There is a theoretical concern that spironolactone may cause feminization of a male fetus; therefore, the drug should not be administered during pregnancy.</p><p></p><p class="bulletIndent1"><a class="drug drug_general" data-topicid="9943" href="/z/d/drug information/9943.html" rel="external">Spironolactone</a> is often given in conjunction with oral contraceptives in premenopausal patients to prevent pregnancy, as well as to reduce menstrual irregularity. Serum potassium levels should be followed periodically in patients over the age of 45 years; in patients with multiple medical problems, cardiac disease, or renal disease; and in patients who are taking medications that may increase risk for hyperkalemia [<a href="#rid17">17,18</a>]. (See  <a class="medical medical_review" href="/z/d/html/129467.html" rel="external">"Acne vulgaris: Management of moderate to severe acne in adolescents and adults", section on 'Adverse effects'</a>.)</p><p></p><p class="bulletIndent1">Although there is a theoretical concern for an elevation in breast cancer risk based upon the estrogenic effects of <a class="drug drug_general" data-topicid="9943" href="/z/d/drug information/9943.html" rel="external">spironolactone</a>, there is no definitive evidence linking human breast tumors, or other estrogen-dependent tumors, to spironolactone therapy [<a href="#rid19">19-21</a>].</p><p></p><p class="headingAnchor" id="H201978428"><span class="h3">Finasteride</span><span class="headingEndMark"> — </span><a class="drug drug_general" data-topicid="8447" href="/z/d/drug information/8447.html" rel="external">Finasteride</a> is a type 2 5-alpha-reductase inhibitor that is frequently used in the treatment of male pattern hair loss. Finasteride inhibits the conversion of testosterone to dihydrotestosterone, thereby reducing the effects of dihydrotestosterone on hair follicles [<a href="#rid22">22</a>] (see  <a class="medical medical_review" href="/z/d/html/3321.html" rel="external">"Male pattern hair loss (androgenetic alopecia in males): Management", section on 'Oral finasteride'</a>):</p><p class="bulletIndent1"><span class="glyph">●</span><strong>Administration</strong> – Typical dosing for <a class="drug drug_general" data-topicid="8447" href="/z/d/drug information/8447.html" rel="external">finasteride</a> for FPHL is 2.5 to 5 mg per day [<a href="#rid23">23</a>]. Clinical signs of response are expected within six months.</p><p></p><p class="bulletIndent1"><span class="glyph">●</span><strong>Efficacy</strong> – Few studies have evaluated the efficacy and safety of <a class="drug drug_general" data-topicid="8447" href="/z/d/drug information/8447.html" rel="external">finasteride</a> in patients with FPHL, and the available studies have utilized varied treatment regimens and have yielded different results [<a href="#rid24">24</a>]. Although a 12-month, placebo-controlled, randomized trial of 137 postmenopausal patients with FPHL and normal serum androgen levels found that treatment with finasteride 1 mg per day did not seem to be of benefit [<a href="#rid25">25</a>], uncontrolled studies utilizing higher doses of finasteride (2.5 or 5 mg per day) have suggested that finasteride may be of benefit in some patients without hyperandrogenism [<a href="#rid26">26-28</a>].</p><p></p><p class="bulletIndent1">The value of <a class="drug drug_general" data-topicid="8447" href="/z/d/drug information/8447.html" rel="external">finasteride</a> in hyperandrogenemic patients with FPHL is also uncertain. A one-year, open-label trial in which 36 premenopausal patients with FPHL and hyperandrogenism were randomized to receive finasteride (5 mg per day), <a class="drug drug_general" data-topicid="8471" href="/z/d/drug information/8471.html" rel="external">flutamide</a> (250 mg per day), or <a class="drug drug_general" data-topicid="9295" href="/z/d/drug information/9295.html" rel="external">cyproterone acetate</a> (50 mg per day for 10 days per month) plus ethinyl estradiol (25 mcg for 20 days per month) found that the results achieved with finasteride were similar to those seen in 12 patients who were recruited to the study but refused therapy [<a href="#rid29">29</a>]. In contrast, in a case series of four patients with hyperandrogenism and hair loss (two premenopausal and two postmenopausal), the condition appeared to stabilize or improve during finasteride therapy [<a href="#rid30">30</a>].</p><p></p><p class="bulletIndent1"><span class="glyph">●</span><strong>Adverse effects</strong> – <a class="drug drug_general" data-topicid="8447" href="/z/d/drug information/8447.html" rel="external">Finasteride</a> is usually well tolerated in female patients [<a href="#rid25">25</a>]. Studies in male patients have included reports of reduced libido and breast swelling or tenderness [<a href="#rid22">22</a>]. Finasteride is also teratogenic; the drug may induce feminization of a male fetus. Thus, treatment with finasteride should be avoided in patients who are pregnant or considering becoming pregnant. When the drug is given to premenopausal patients who may become pregnant, the use of reliable contraception is indicated.</p><p></p><p class="headingAnchor" id="H2651401664"><span class="h3">Cyproterone acetate</span><span class="headingEndMark"> — </span><a class="drug drug_general" data-topicid="9295" href="/z/d/drug information/9295.html" rel="external">Cyproterone acetate</a> is an antiandrogen that may be effective for FPHL. Cyproterone acetate is not available in the United States:</p><p class="bulletIndent1"><span class="glyph">●</span><strong>Administration</strong> – The dosing regimen for <a class="drug drug_general" data-topicid="9295" href="/z/d/drug information/9295.html" rel="external">cyproterone acetate</a> for FPHL is not standardized. When used in the treatment of FPHL, some authors have suggested the following regimens for premenopausal patients [<a href="#rid31">31</a>]: </p><p></p><p class="bulletIndent2"><span class="glyph">•</span>100 mg per day on days 5 to 15 of the menstrual cycle and 50 mcg of ethinyl estradiol on days 5 to 25</p><p></p><p class="bulletIndent2"><strong>Or</strong></p><p></p><p class="bulletIndent2"><span class="glyph">•</span>50 mg of <a class="drug drug_general" data-topicid="9295" href="/z/d/drug information/9295.html" rel="external">cyproterone acetate</a> on days 1 to 10 and 35 mcg on ethinyl estradiol on days 1 to 21</p><p></p><p class="bulletIndent1">Postmenopausal patients may be treated with 50 mg daily [<a href="#rid10">10</a>].</p><p></p><p class="bulletIndent1"><span class="glyph">●</span><strong>Efficacy</strong> – The efficacy of <a class="drug drug_general" data-topicid="9295" href="/z/d/drug information/9295.html" rel="external">cyproterone acetate</a> in FPHL is difficult to assess since studies evaluating the efficacy of the drug have used variable treatment regimens and have yielded mixed results [<a href="#rid10">10,29,32-34</a>]. As mentioned above, an open-label study of 80 premenopausal and postmenopausal patients (most with normal androgen levels) that compared treatment with cyproterone acetate and <a class="drug drug_general" data-topicid="9943" href="/z/d/drug information/9943.html" rel="external">spironolactone</a> found that both treatments appeared to be effective and did not find a significant difference in efficacy between the two groups [<a href="#rid10">10</a>]. (See <a class="local">'Spironolactone'</a> above.)</p><p></p><p class="bulletIndent1">In contrast, a randomized trial raised questions about the efficacy of <a class="drug drug_general" data-topicid="9295" href="/z/d/drug information/9295.html" rel="external">cyproterone acetate</a> for FPHL. In the one-year trial, 66 premenopausal patients (many with acne, hirsutism, or menstrual cycle irregularities) were randomized to receive either topical <a class="drug drug_general" data-topicid="9655" href="/z/d/drug information/9655.html" rel="external">minoxidil</a> 2% solution plus an oral contraceptive containing ethinyl estradiol and gestodene or cyproterone acetate (50 mg per day for 20 days per menstrual cycle) plus an oral contraceptive containing ethinyl estradiol and 2 mg of cyproterone acetate [<a href="#rid32">32</a>]. While minoxidil appeared to be effective for inducing hair regrowth (change in hair count between first and last measurement = 7.7±9.3 per 0.36 cm<sup>2</sup>), statistically significant hair regrowth did not occur in the cyproterone acetate group (change in hair count between first and last measurement = -0.2±6.7 per 0.36 cm<sup>2</sup>). Among patients treated with cyproterone acetate, patients with irregular menstrual cycles seemed to respond better than patients without irregular menstrual cycles; however, this difference was not statistically significant.</p><p></p><p class="bulletIndent1"><span class="glyph">●</span><strong>Adverse effects</strong> – Potential side effects of <a class="drug drug_general" data-topicid="9295" href="/z/d/drug information/9295.html" rel="external">cyproterone acetate</a> include menstrual cycle irregularity, weight gain, breast tenderness, reduced libido, depression, and nausea [<a href="#rid31">31</a>]. Cyproterone acetate should not be taken during pregnancy.</p><p></p><p class="headingAnchor" id="H1690568426"><span class="h2">Additional interventions</span></p><p class="headingAnchor" id="H3596187765"><span class="h3">Patients with hyperandrogenism</span><span class="headingEndMark"> — </span>Treatment of the underlying, hyperandrogenic state is important for improving FPHL associated with hyperandrogenism. FPHL therapies that are not antiandrogenic, such as topical <a class="drug drug_general" data-topicid="9655" href="/z/d/drug information/9655.html" rel="external">minoxidil</a>, may also be beneficial [<a href="#rid23">23</a>]. A frequent approach to FPHL related to polycystic ovarian syndrome (a common cause of hyperandrogenism in females) is the addition of topical minoxidil and <a class="drug drug_general" data-topicid="9943" href="/z/d/drug information/9943.html" rel="external">spironolactone</a> when oral contraceptive therapy yields insufficient improvement. (See  <a class="medical medical_review" href="/z/d/html/7436.html" rel="external">"Clinical manifestations of polycystic ovary syndrome in adults"</a> and  <a class="medical medical_review" href="/z/d/html/7421.html" rel="external">"Treatment of polycystic ovary syndrome in adults", section on 'Androgen excess'</a>.)</p><p class="headingAnchor" id="H10505091"><span class="h3">Patients with concomitant scalp disorders</span><span class="headingEndMark"> — </span>Treatment of coexisting inflammatory scalp conditions, such as seborrheic dermatitis, is generally advised to minimize additional hair loss related to scalp inflammation. In our experience, successful treatment of seborrheic dermatitis seems to reduce risk for skin irritation from topical <a class="drug drug_general" data-topicid="9655" href="/z/d/drug information/9655.html" rel="external">minoxidil</a>. (See  <a class="medical medical_review" href="/z/d/html/13669.html" rel="external">"Seborrheic dermatitis in adolescents and adults", section on 'Management'</a>.)</p><p class="headingAnchor" id="H1968084409"><span class="h1">FAILURE OF INITIAL THERAPY</span></p><p class="headingAnchor" id="H2205515730"><span class="h2">General approach</span><span class="headingEndMark"> — </span>When hair density fails to improve despite combination treatment with topical <a class="drug drug_general" data-topicid="9655" href="/z/d/drug information/9655.html" rel="external">minoxidil</a> and an oral antiandrogen, we incorporate other therapies, such as platelet-rich plasma (PRP) injections, low-level laser therapy (LLLT), and oral minoxidil  (<a class="graphic graphic_algorithm graphicRef134317" href="/z/d/graphic/134317.html" rel="external">algorithm 1</a>). We typically continue topical minoxidil and oral antiandrogenic drugs, with the exception of the discontinuation of topical minoxidil for patients starting oral minoxidil. Efficacy of these therapies may be assessed after six months. Hair transplantation is an alternative for patients who fail medical therapy. (See <a class="local">'Platelet-rich plasma'</a> below and <a class="local">'Low-level laser therapy'</a> below and <a class="local">'Oral minoxidil'</a> below and <a class="local">'Hair transplantation'</a> below.)</p><p>Patient preference strongly influences the selection among these therapies. PRP and LLLT may be favored by patients who prefer to avoid systemic therapy. Oral <a class="drug drug_general" data-topicid="9655" href="/z/d/drug information/9655.html" rel="external">minoxidil</a> may be favored by patients who experience skin irritation from topical minoxidil or dislike daily application of topical minoxidil therapy. The cost of PRP therapy, LLLT devices, and hair transplantation can be limiting for some patients.</p><p>Although combination antiandrogenic therapy is used by some clinicians, data to confirm superior efficacy of combination antiandrogenic therapy (eg, <a class="drug drug_general" data-topicid="9943" href="/z/d/drug information/9943.html" rel="external">spironolactone</a> and <a class="drug drug_general" data-topicid="8447" href="/z/d/drug information/8447.html" rel="external">finasteride</a>) over antiandrogen monotherapy are lacking. We treat most patients with a single antiandrogenic agent, reserving combination therapy for occasional, treatment-refractory cases.</p><p class="headingAnchor" id="H628369229"><span class="h2">Platelet-rich plasma</span><span class="headingEndMark"> — </span>Platelet-rich plasma (PRP) has been utilized for the treatment of male and female pattern hair loss (FPHL). PRP therapy is based upon the concept that growth factors released from platelets may modulate hair cycle signaling pathways that contribute to regrowth of hair [<a href="#rid35">35</a>]. Additional study is necessary to confirm the effects of PRP and determine optimal treatment regimen:</p><p class="bulletIndent1"><span class="glyph">●</span><strong>Administration</strong> – Approaches to PRP vary [<a href="#rid36">36</a>]. In general, whole blood drawn from the patient is centrifuged to separate platelets and plasma from other blood products. In some protocols, <a class="drug drug_general" data-topicid="9186" href="/z/d/drug information/9186.html" rel="external">calcium chloride</a> is used to activate PRP to stimulate the release of growth factors. The PRP is subsequently injected into the patient's scalp.</p><p></p><p class="bulletIndent1"><span class="glyph">●</span><strong>Efficacy</strong> – Although there are data that suggest benefit, studies evaluating this approach for FPHL are limited, and uncertainty remains regarding the role of this treatment [<a href="#rid36">36-42</a>]. Randomized trials evaluating PRP have generally been small and have used widely varying treatment regimens and PRP devices.</p><p></p><p class="bulletIndent1">Examples of trials assessing the efficacy of PRP include:</p><p></p><p class="bulletIndent2"><span class="glyph">•</span>A 24-week trial in which 30 patients with FPHL were randomly assigned to three monthly treatments with PRP or placebo found patients treated with PRP more likely to demonstrate improvement in clinical photographs (57 versus 7 percent) and found greater improvement in hair density and hair caliber in the PRP group, suggesting benefit of PRP [<a href="#rid43">43</a>].</p><p></p><p class="bulletIndent2"><span class="glyph">•</span>A placebo-controlled, randomized, split-scalp trial that included 12 males and 13 females with androgenetic alopecia found a greater increase in the mean total hair density in sites treated with PRP compared with control sites six months after the first of three monthly PRP treatments [<a href="#rid42">42</a>]. However, differences in percentage of anagen hairs, percentage of telogen hairs, anagen/telogen hair ratio, terminal hair density, and hair count between the treated and control areas were not statistically significant.</p><p></p><p class="bulletIndent2"><span class="glyph">•</span>A split-scalp trial in which 17 females and 18 males with androgenetic alopecia received three monthly treatments with PRP in one scalp area and <a class="drug drug_general" data-topicid="9929" href="/z/d/drug information/9929.html" rel="external">saline</a> treatments in a second scalp area did not find a difference in hair density change between the two groups three months after the last treatment [<a href="#rid35">35</a>]. Both PRP- and saline-treated areas demonstrated increased hair density. The authors postulated that diffusion of PRP from relatively large treatment areas or a beneficial effect of wounding from injections may have contributed to the absence of a significant difference in effect between the groups.</p><p></p><p class="bulletIndent1"><span class="glyph">●</span><strong>Adverse effects</strong> – The injections for delivery of PRP into the scalp can cause discomfort [<a href="#rid35">35</a>]. Other potential adverse events include headache; postinjection bleeding; and scalp discomfort, redness, or swelling [<a href="#rid43">43</a>].</p><p></p><p class="headingAnchor" id="H3816815586"><span class="h2">Low-level laser therapy</span><span class="headingEndMark"> — </span>Low-level laser therapy (LLLT), also referred to as "photobiomodulation therapy," may be of benefit for FPHL [<a href="#rid44">44</a>]. The mechanism of effect is unclear. Acceleration of cellular mitosis, stimulation of hair follicle stem cells or follicular keratinocytes, effects on cell metabolism leading to increased adenosine triphosphate production and cellular activity, and anti-inflammatory effects are postulated to contribute [<a href="#rid45">45</a>]. LLLT has also been used for male pattern hair loss [<a href="#rid46">46</a>]. (See  <a class="medical medical_review" href="/z/d/html/3321.html" rel="external">"Male pattern hair loss (androgenetic alopecia in males): Management", section on 'Photobiomodulation'</a>.) </p><p>Two 26-week trials in which a total of 141 patients with FPHL were randomly assigned to use of either one of two models of an LLLT comb device three times per week or to similar treatment with a sham device found greater improvements in terminal hair density among patients treated with LLLT combs than among patients given sham treatment [<a href="#rid45">45</a>]. Similarly, a 24-week trial in which 20 males and 20 females with androgenetic alopecia were randomly assigned to treatment with a laser helmet or sham device found the laser helmet more effective for increasing hair density and hair diameter [<a href="#rid47">47</a>]. Other studies suggest greater efficacy of combined topical <a class="drug drug_general" data-topicid="9655" href="/z/d/drug information/9655.html" rel="external">minoxidil</a> and LLLT therapy over topical minoxidil monotherapy [<a href="#rid48">48,49</a>].</p><p class="headingAnchor" id="H242379242"><span class="h2">Oral minoxidil</span><span class="headingEndMark"> — </span>Limited data suggest oral <a class="drug drug_general" data-topicid="9655" href="/z/d/drug information/9655.html" rel="external">minoxidil</a> may be an alternative treatment for FPHL [<a href="#rid50">50-53</a>]. A 24-week, open-label trial that randomly assigned 52 patients with FPHL to either oral minoxidil (1 mg per day) or once-daily application of minoxidil 5% solution did not find a statistically significant difference in effect on total hair density (12 versus 7 percent increase, respectively) [<a href="#rid50">50</a>]. However, the adverse event of mild hypertrichosis occurred more frequently in the oral minoxidil group than in the topical minoxidil group (27 versus 4 percent). Other adverse events in the oral minoxidil group included a slight increase in mean heart rate at rest and one occurrence of pretibial edema.</p><p class="headingAnchor" id="H2792927722"><span class="h1">HAIR TRANSPLANTATION</span><span class="headingEndMark"> — </span>Surgical interventions similar to those performed for male pattern hair loss are an option for patients with female pattern hair loss (FPHL) who do not achieve a satisfactory response with pharmacologic therapy  (<a class="graphic graphic_algorithm graphicRef134317" href="/z/d/graphic/134317.html" rel="external">algorithm 1</a>) [<a href="#rid54">54-57</a>]. Through the transplantation of terminal hairs from unaffected areas of the scalp to affected sites, patients can achieve cosmetically favorable improvements.</p><p>Disadvantages of hair transplantation include high cost; significant time investment for patients; side effects such as early, temporary hair loss, pain, and infection; and the potential for transplant failure. Some patients with FPHL are poor candidates for hair transplantation, including patients with diffuse hair loss or in whom hair density in the donor area (typically the posterior scalp) is insufficient [<a href="#rid55">55</a>]. (See  <a class="medical medical_review" href="/z/d/html/3321.html" rel="external">"Male pattern hair loss (androgenetic alopecia in males): Management"</a>.)</p><p class="headingAnchor" id="H1923138399"><span class="h1">OTHER THERAPIES</span><span class="headingEndMark"> — </span>Insufficient efficacy data or concern for adverse effects inhibit the routine use of other therapies:</p><p class="bulletIndent1"><span class="glyph">●</span><strong>Prostaglandin analogs</strong> – <a class="drug drug_general" data-topicid="9547" href="/z/d/drug information/9547.html" rel="external">Latanoprost</a> 0.1%, a topical prostaglandin analog, was reported to increase hair density in a small, randomized trial of male patients with androgenetic alopecia [<a href="#rid58">58</a>]. In a case report, injections of <a class="drug drug_general" data-topicid="8931" href="/z/d/drug information/8931.html" rel="external">bimatoprost</a>, another prostaglandin analog, were not effective in a patient with female pattern hair loss (FPHL) [<a href="#rid59">59</a>].</p><p></p><p class="bulletIndent1"><span class="glyph">●</span><strong>Topical </strong><strong>finasteride</strong> – In a 24-week trial in which 30 postmenopausal females were randomly assigned to either topical <a class="drug drug_general" data-topicid="8447" href="/z/d/drug information/8447.html" rel="external">finasteride</a> 0.25% combined with <a class="drug drug_general" data-topicid="9655" href="/z/d/drug information/9655.html" rel="external">minoxidil</a> 3% solution or minoxidil 3% solution alone, combination therapy was associated with a greater increase in hair diameter compared with minoxidil alone [<a href="#rid60">60</a>]. Of note, serum dihydrotestosterone levels decreased in the combination therapy group.</p><p></p><p class="bulletIndent1"><span class="glyph">●</span><strong>Dutasteride</strong> – Oral <a class="drug drug_general" data-topicid="8672" href="/z/d/drug information/8672.html" rel="external">dutasteride</a>, a type 1 and type 2 5-alpha-reductase inhibitor, appeared effective in a 46-year-old female patient who had attained only minimal improvement in FPHL with <a class="drug drug_general" data-topicid="8447" href="/z/d/drug information/8447.html" rel="external">finasteride</a> [<a href="#rid61">61</a>].</p><p></p><p class="bulletIndent1"><span class="glyph">●</span><strong>Flutamide</strong> – <a class="drug drug_general" data-topicid="8471" href="/z/d/drug information/8471.html" rel="external">Flutamide</a> is an antiandrogenic agent infrequently utilized for the treatment of FPHL. A few studies have found evidence in support of its efficacy [<a href="#rid29">29,62-64</a>]. In a prospective cohort study of 101 premenopausal patients with FPHL (including 12 with elevated testosterone levels at baseline) who were treated with flutamide (250 mg for one year, 125 mg for one year, then 62.5 mg per day for two years), statistically significant improvement in hair loss severity scores was detected within six months, and continued improvement was noted up to two years [<a href="#rid63">63</a>]. The mean percentage improvement was 15 percent at six months and 28 percent at two years.</p><p></p><p class="bulletIndent1">Potential side effects of <a class="drug drug_general" data-topicid="8471" href="/z/d/drug information/8471.html" rel="external">flutamide</a> include reduced libido, gastrointestinal distress, and liver function test abnormalities [<a href="#rid63">63</a>]. Hepatic failure is a rare side effect, and concern regarding this possibility has limited the use of flutamide therapy. However, significant elevations in transaminases were seen in only 4 percent of patients in the prospective cohort study, and the transaminase abnormalities resolved rapidly after treatment cessation [<a href="#rid63">63</a>].</p><p></p><p class="bulletIndent1"><span class="glyph">●</span><strong>Other</strong> – Although <a class="drug drug_general" data-topicid="120386" href="/z/d/drug information/120386.html" rel="external">biotin</a> supplementation is commonly marketed for hair loss, evidence to support efficacy in FPHL is lacking. We do <strong>not </strong>use biotin supplementation for the treatment of FPHL.</p><p></p><p class="bulletIndent1">Similarly, the efficacy of other supplements (eg, iron, ginseng, saw palmetto, green tea, and <a class="drug drug_general" data-topicid="9213" href="/z/d/drug information/9213.html" rel="external">caffeine</a>), mesotherapy, microneedling, topical estrogens, and topical <a class="drug drug_general" data-topicid="9817" href="/z/d/drug information/9817.html" rel="external">progesterone</a> on FPHL are unclear [<a href="#rid7">7,65</a>].</p><p></p><p class="headingAnchor" id="H705297125"><span class="h1">COSMETIC OPTIONS</span><span class="headingEndMark"> — </span>Patients with female pattern hair loss (FPHL) who are bothered by the appearance of hair loss may benefit from cosmetic interventions. Consultation with a cosmetologist may be helpful for identifying techniques to minimize the cosmetic impact of hair loss. Interventions such as hair styling techniques, hair dyeing, hair fibers, scalp micropigmentation, thickening shampoos, and wigs or other hair prostheses may be helpful.</p><p class="headingAnchor" id="H633853734"><span class="h1">PROGNOSIS</span><span class="headingEndMark"> — </span>Once female pattern hair loss (FPHL) develops, the condition typically progresses over time, resulting in diminishing coverage of affected areas of the scalp by hair. Unlike male pattern hair loss, progression to complete baldness usually does not occur.</p><p class="headingAnchor" id="H3286216843"><span class="h1">SOCIETY GUIDELINE LINKS</span><span class="headingEndMark"> — </span>Links to society and government-sponsored guidelines from selected countries and regions around the world are provided separately. (See  <a class="medical medical_society_guidelines" href="/z/d/html/117218.html" rel="external">"Society guideline links: Alopecia"</a>.)</p><p class="headingAnchor" id="H633857058"><span class="h1">SUMMARY AND RECOMMENDATIONS</span></p><p class="bulletIndent1"><span class="glyph">●</span><strong>Overview</strong> – Female pattern hair loss (FPHL) is a common form of nonscarring hair loss that typically occurs in adult females  (<a class="graphic graphic_picture graphicRef87193 graphicRef87194 graphicRef87195" href="/z/d/graphic/87193.html" rel="external">picture 1A-C</a>). The characteristic feature is the progressive loss of terminal hairs over the frontal and vertex regions of the scalp, leading to a visible reduction in hair density. Topical, systemic, and surgical therapies have been used for the management of FPHL. (See <a class="local">'Introduction'</a> above and <a class="local">'Prognosis'</a> above.) </p><p></p><p class="bulletIndent1"><span class="glyph">●</span><strong>Treatment principles</strong> – The goals of treatment of FPHL include cessation of progression of hair loss and improvement in terminal hair density that is cosmetically satisfactory for the patient. Responses to treatment vary, and at least several months of treatment are often necessary to achieve a noticeable response. Initiating treatment early, prior to the development of extensive hair loss, is preferred given the potential for incomplete responses. Topical <a class="drug drug_general" data-topicid="9655" href="/z/d/drug information/9655.html" rel="external">minoxidil</a> and oral antiandrogenic therapy are the mainstays of treatment. (See <a class="local">'Treatment principles'</a> above.)</p><p></p><p class="bulletIndent1"><span class="glyph">●</span><strong>Patients with hyperandrogenism</strong> – A minority of patients with FPHL have associated hyperandrogenism. Identification and treatment of the underlying, hyperandrogenic state is an important component of the treatment of FPHL in these patients. (See <a class="local">'Patients with hyperandrogenism'</a> above.)</p><p></p><p class="bulletIndent1"><span class="glyph">●</span><strong>Initial treatment</strong> – For patients with FPHL, we recommend topical <a class="drug drug_general" data-topicid="9655" href="/z/d/drug information/9655.html" rel="external">minoxidil</a> (<a class="grade" href="https:///uptodate/show/grade_2" rel="external">Grade 1B</a>)  (<a class="graphic graphic_algorithm graphicRef134317" href="/z/d/graphic/134317.html" rel="external">algorithm 1</a>). We also suggest the addition of <a class="drug drug_general" data-topicid="9943" href="/z/d/drug information/9943.html" rel="external">spironolactone</a> to topical minoxidil, rather than topical minoxidil monotherapy (<a class="grade" href="https:///uptodate/show/grade_6" rel="external">Grade 2C</a>). </p><p></p><p class="bulletIndent1">Topical <a class="drug drug_general" data-topicid="9655" href="/z/d/drug information/9655.html" rel="external">minoxidil</a> has the strongest evidence for efficacy and is generally well tolerated. <a class="drug drug_general" data-topicid="9943" href="/z/d/drug information/9943.html" rel="external">Spironolactone</a> is our preferred oral antiandrogen for FPHL based upon data that suggest benefit and the extensive experience with this drug in females for other indications. </p><p></p><p class="bulletIndent1"><a class="drug drug_general" data-topicid="8447" href="/z/d/drug information/8447.html" rel="external">Finasteride</a> and <a class="drug drug_general" data-topicid="9295" href="/z/d/drug information/9295.html" rel="external">cyproterone acetate</a> are alternative oral antiandrogens. We tend to use finasteride when patients do not tolerate <a class="drug drug_general" data-topicid="9943" href="/z/d/drug information/9943.html" rel="external">spironolactone</a>, prefer to avoid spironolactone, or have a poor response to spironolactone. Cyproterone acetate is not available in the United States. (See <a class="local">'Adjunctive oral therapy'</a> above.)</p><p></p><p class="bulletIndent1"><span class="glyph">●</span><strong>Failure of initial treatment</strong> – The best approach to patients who fail to achieve sufficient improvement with topical <a class="drug drug_general" data-topicid="9655" href="/z/d/drug information/9655.html" rel="external">minoxidil</a> plus an oral antiandrogen is unclear. Our typical approach consists of the addition of platelet-rich plasma (PRP) injections, the addition of low-level laser therapy (LLLT), or the replacement of topical minoxidil with oral minoxidil  (<a class="graphic graphic_algorithm graphicRef134317" href="/z/d/graphic/134317.html" rel="external">algorithm 1</a>). Patient preference strongly influences treatment selection. (See <a class="local">'Failure of initial therapy'</a> above.)</p><p></p><p class="bulletIndent1"><span class="glyph">●</span><strong>Hair transplantation</strong> – Hair transplantation surgery can provide cosmetically favorable results in patients with FPHL. Surgical intervention is an option for patients who fail to achieve satisfactory improvement with pharmacologic therapy  (<a class="graphic graphic_algorithm graphicRef134317" href="/z/d/graphic/134317.html" rel="external">algorithm 1</a>). (See <a class="local">'Hair transplantation'</a> above.)</p></div><div class="headingAnchor" id="references"><ol id="reference"><li><a class="nounderline abstract_t">Adil A, Godwin M. The effectiveness of treatments for androgenetic alopecia: A systematic review and meta-analysis. J Am Acad Dermatol 2017; 77:136.</a></li><li><a class="nounderline abstract_t">van Zuuren EJ, Fedorowicz Z, Schoones J. Interventions for female pattern hair loss. Cochrane Database Syst Rev 2016; :CD007628.</a></li><li><a class="nounderline abstract_t">Blume-Peytavi U, Hillmann K, Dietz E, et al. A randomized, single-blind trial of 5% minoxidil foam once daily versus 2% minoxidil solution twice daily in the treatment of androgenetic alopecia in women. J Am Acad Dermatol 2011; 65:1126.</a></li><li><a class="nounderline abstract_t">Bergfeld W, Washenik K, Callender V, et al. A Phase III, Multicenter, Parallel-Design Clinical Trial to Compare the Efficacy and Safety of 5% Minoxidil Foam Versus Vehicle in Women With Female Pattern Hair Loss. J Drugs Dermatol 2016; 15:874.</a></li><li><a class="nounderline abstract_t">Olsen EA, Messenger AG, Shapiro J, et al. Evaluation and treatment of male and female pattern hair loss. J Am Acad Dermatol 2005; 52:301.</a></li><li><a class="nounderline abstract_t">Messenger AG, Rundegren J. Minoxidil: mechanisms of action on hair growth. Br J Dermatol 2004; 150:186.</a></li><li><a class="nounderline abstract_t">Blumeyer A, Tosti A, Messenger A, et al. Evidence-based (S3) guideline for the treatment of androgenetic alopecia in women and in men. J Dtsch Dermatol Ges 2011; 9 Suppl 6:S1.</a></li><li><a class="nounderline abstract_t">Rathnayake D, Sinclair R. Innovative use of spironolactone as an antiandrogen in the treatment of female pattern hair loss. Dermatol Clin 2010; 28:611.</a></li><li><a class="nounderline abstract_t">Sinclair R, Patel M, Dawson TL Jr, et al. Hair loss in women: medical and cosmetic approaches to increase scalp hair fullness. Br J Dermatol 2011; 165 Suppl 3:12.</a></li><li><a class="nounderline abstract_t">Sinclair R, Wewerinke M, Jolley D. Treatment of female pattern hair loss with oral antiandrogens. Br J Dermatol 2005; 152:466.</a></li><li><a class="nounderline abstract_t">Burke BM, Cunliffe WJ. Oral spironolactone therapy for female patients with acne, hirsutism or androgenic alopecia. Br J Dermatol 1985; 112:124.</a></li><li><a class="nounderline abstract_t">Yazdabadi A, Green J, Sinclair R. Successful treatment of female-pattern hair loss with spironolactone in a 9-year-old girl. Australas J Dermatol 2009; 50:113.</a></li><li><a class="nounderline abstract_t">Hoedemaker C, van Egmond S, Sinclair R. Treatment of female pattern hair loss with a combination of spironolactone and minoxidil. Australas J Dermatol 2007; 48:43.</a></li><li><a class="nounderline abstract_t">Adamopoulos DA, Karamertzanis M, Nicopoulou S, Gregoriou A. Beneficial effect of spironolactone on androgenic alopecia. Clin Endocrinol (Oxf) 1997; 47:759.</a></li><li><a class="nounderline abstract_t">Famenini S, Slaught C, Duan L, Goh C. Demographics of women with female pattern hair loss and the effectiveness of spironolactone therapy. J Am Acad Dermatol 2015; 73:705.</a></li><li><a class="nounderline abstract_t">Burns LJ, De Souza B, Flynn E, et al. Spironolactone for treatment of female pattern hair loss. J Am Acad Dermatol 2020; 83:276.</a></li><li><a class="nounderline abstract_t">Plovanich M, Weng QY, Mostaghimi A. Low Usefulness of Potassium Monitoring Among Healthy Young Women Taking Spironolactone for Acne. JAMA Dermatol 2015; 151:941.</a></li><li><a class="nounderline abstract_t">Thiede RM, Rastogi S, Nardone B, et al. Hyperkalemia in women with acne exposed to oral spironolactone: A retrospective study from the RADAR (Research on Adverse Drug Events and Reports) program. Int J Womens Dermatol 2019; 5:155.</a></li><li><a class="nounderline abstract_t">Wei C, Bovonratwet P, Gu A, et al. Spironolactone use does not increase the risk of female breast cancer recurrence: A retrospective analysis. J Am Acad Dermatol 2020; 83:1021.</a></li><li><a class="nounderline abstract_t">Biggar RJ, Andersen EW, Wohlfahrt J, Melbye M. Spironolactone use and the risk of breast and gynecologic cancers. Cancer Epidemiol 2013; 37:870.</a></li><li><a class="nounderline abstract_t">Mackenzie IS, Morant SV, Wei L, et al. Spironolactone use and risk of incident cancers: a retrospective, matched cohort study. Br J Clin Pharmacol 2017; 83:653.</a></li><li><a class="nounderline abstract_t">Stout SM, Stumpf JL. Finasteride treatment of hair loss in women. Ann Pharmacother 2010; 44:1090.</a></li><li><a class="nounderline abstract_t">Carmina E, Azziz R, Bergfeld W, et al. Female Pattern Hair Loss and Androgen Excess: A Report From the Multidisciplinary Androgen Excess and PCOS Committee. J Clin Endocrinol Metab 2019; 104:2875.</a></li><li><a class="nounderline abstract_t">Iamsumang W, Leerunyakul K, Suchonwanit P. Finasteride and Its Potential for the Treatment of Female Pattern Hair Loss: Evidence to Date. Drug Des Devel Ther 2020; 14:951.</a></li><li><a class="nounderline abstract_t">Price VH, Roberts JL, Hordinsky M, et al. Lack of efficacy of finasteride in postmenopausal women with androgenetic alopecia. J Am Acad Dermatol 2000; 43:768.</a></li><li><a class="nounderline abstract_t">Iorizzo M, Vincenzi C, Voudouris S, et al. Finasteride treatment of female pattern hair loss. Arch Dermatol 2006; 142:298.</a></li><li><a class="nounderline abstract_t">Yeon JH, Jung JY, Choi JW, et al. 5 mg/day finasteride treatment for normoandrogenic Asian women with female pattern hair loss. J Eur Acad Dermatol Venereol 2011; 25:211.</a></li><li><a class="nounderline abstract_t">Trüeb RM, Swiss Trichology Study Group. Finasteride treatment of patterned hair loss in normoandrogenic postmenopausal women. Dermatology 2004; 209:202.</a></li><li><a class="nounderline abstract_t">Carmina E, Lobo RA. Treatment of hyperandrogenic alopecia in women. Fertil Steril 2003; 79:91.</a></li><li><a class="nounderline abstract_t">Shum KW, Cullen DR, Messenger AG. Hair loss in women with hyperandrogenism: four cases responding to finasteride. J Am Acad Dermatol 2002; 47:733.</a></li><li class="breakAll">Otberg N, Shapiro J. Hair growth disorders. In: Fitzpatrick's Dermatology in General Medicine, 8th ed, Goldsmith LA, Katz SI, Gilchrest BA, et al (Eds), McGraw-Hill, 2012. Vol 1, p.979.</li><li><a class="nounderline abstract_t">Vexiau P, Chaspoux C, Boudou P, et al. Effects of minoxidil 2% vs. cyproterone acetate treatment on female androgenetic alopecia: a controlled, 12-month randomized trial. Br J Dermatol 2002; 146:992.</a></li><li><a class="nounderline abstract_t">Peereboom-Wynia JD, van der Willigen AH, van Joost T, Stolz E. The effect of cyproterone acetate on hair roots and hair shaft diameter in androgenetic alopecia in females. Acta Derm Venereol 1989; 69:395.</a></li><li><a class="nounderline abstract_t">Rushton DH, Ramsay ID. The importance of adequate serum ferritin levels during oral cyproterone acetate and ethinyl oestradiol treatment of diffuse androgen-dependent alopecia in women. Clin Endocrinol (Oxf) 1992; 36:421.</a></li><li><a class="nounderline abstract_t">Shapiro J, Ho A, Sukhdeo K, et al. Evaluation of platelet-rich plasma as a treatment for androgenetic alopecia: A randomized controlled trial. J Am Acad Dermatol 2020; 83:1298.</a></li><li><a class="nounderline abstract_t">Gupta AK, Cole J, Deutsch DP, et al. Platelet-Rich Plasma as a Treatment for Androgenetic Alopecia. Dermatol Surg 2019; 45:1262.</a></li><li><a class="nounderline abstract_t">Giordano S, Romeo M, Lankinen P. Platelet-rich plasma for androgenetic alopecia: Does it work? Evidence from meta analysis. J Cosmet Dermatol 2017; 16:374.</a></li><li><a class="nounderline abstract_t">Gupta AK, Carviel JL. Meta-analysis of efficacy of platelet-rich plasma therapy for androgenetic alopecia. J Dermatolog Treat 2017; 28:55.</a></li><li><a class="nounderline abstract_t">Hausauer AK, Jones DH. Evaluating the Efficacy of Different Platelet-Rich Plasma Regimens for Management of Androgenetic Alopecia: A Single-Center, Blinded, Randomized Clinical Trial. Dermatol Surg 2018; 44:1191.</a></li><li><a class="nounderline abstract_t">Gupta AK, Mays RR, Dotzert MS, et al. Efficacy of non-surgical treatments for androgenetic alopecia: a systematic review and network meta-analysis. J Eur Acad Dermatol Venereol 2018; 32:2112.</a></li><li><a class="nounderline abstract_t">Gupta AK, Renaud HJ, Bamimore M. Platelet-rich plasma for androgenetic alopecia: Efficacy differences between men and women. Dermatol Ther 2020; 33:e14143.</a></li><li><a class="nounderline abstract_t">Alves R, Grimalt R. Randomized Placebo-Controlled, Double-Blind, Half-Head Study to Assess the Efficacy of Platelet-Rich Plasma on the Treatment of Androgenetic Alopecia. Dermatol Surg 2016; 42:491.</a></li><li><a class="nounderline abstract_t">Dubin DP, Lin MJ, Leight HM, et al. The effect of platelet-rich plasma on female androgenetic alopecia: A randomized controlled trial. J Am Acad Dermatol 2020; 83:1294.</a></li><li><a class="nounderline abstract_t">Egger A, Resnik SR, Aickara D, et al. Examining the Safety and Efficacy of Low-Level Laser Therapy for Male and Female Pattern Hair Loss: A Review of the Literature. Skin Appendage Disord 2020; 6:259.</a></li><li><a class="nounderline abstract_t">Jimenez JJ, Wikramanayake TC, Bergfeld W, et al. Efficacy and safety of a low-level laser device in the treatment of male and female pattern hair loss: a multicenter, randomized, sham device-controlled, double-blind study. Am J Clin Dermatol 2014; 15:115.</a></li><li><a class="nounderline abstract_t">Leavitt M, Charles G, Heyman E, Michaels D. HairMax LaserComb laser phototherapy device in the treatment of male androgenetic alopecia: A randomized, double-blind, sham device-controlled, multicentre trial. Clin Drug Investig 2009; 29:283.</a></li><li><a class="nounderline abstract_t">Suchonwanit P, Chalermroj N, Khunkhet S. Low-level laser therapy for the treatment of androgenetic alopecia in Thai men and women: a 24-week, randomized, double-blind, sham device-controlled trial. Lasers Med Sci 2019; 34:1107.</a></li><li><a class="nounderline abstract_t">Faghihi G, Mozafarpoor S, Asilian A, et al. The effectiveness of adding low-level light therapy to minoxidil 5% solution in the treatment of patients with androgenetic alopecia. Indian J Dermatol Venereol Leprol 2018; 84:547.</a></li><li><a class="nounderline abstract_t">Liu Y, Jiang LL, Liu F, et al. Comparison of low-level light therapy and combination therapy of 5% minoxidil in the treatment of female pattern hair loss. Lasers Med Sci 2021; 36:1085.</a></li><li><a class="nounderline abstract_t">Ramos PM, Sinclair RD, Kasprzak M, Miot HA. Minoxidil 1 mg oral versus minoxidil 5% topical solution for the treatment of female-pattern hair loss: A randomized clinical trial. J Am Acad Dermatol 2020; 82:252.</a></li><li><a class="nounderline abstract_t">Sinclair RD. Female pattern hair loss: a pilot study investigating combination therapy with low-dose oral minoxidil and spironolactone. Int J Dermatol 2018; 57:104.</a></li><li><a class="nounderline abstract_t">Beach RA. Case series of oral minoxidil for androgenetic and traction alopecia: Tolerability &amp; the five C's of oral therapy. Dermatol Ther 2018; 31:e12707.</a></li><li><a class="nounderline abstract_t">Olamiju B, Craiglow BG. Combination oral minoxidil and spironolactone for the treatment of androgenetic alopecia in adolescent girls. J Am Acad Dermatol 2021; 84:1689.</a></li><li><a class="nounderline abstract_t">Epstein JS. The treatment of female pattern hair loss and other applications of surgical hair restoration in women. Facial Plast Surg Clin North Am 2004; 12:241.</a></li><li><a class="nounderline abstract_t">Unger WP, Unger RH. Hair transplanting: an important but often forgotten treatment for female pattern hair loss. J Am Acad Dermatol 2003; 49:853.</a></li><li><a class="nounderline abstract_t">Avram MR. Hair transplantation for men and women. Semin Cutan Med Surg 2006; 25:60.</a></li><li><a class="nounderline abstract_t">Callender VD, McMichael AJ, Cohen GF. Medical and surgical therapies for alopecias in black women. Dermatol Ther 2004; 17:164.</a></li><li><a class="nounderline abstract_t">Blume-Peytavi U, Lönnfors S, Hillmann K, Garcia Bartels N. A randomized double-blind placebo-controlled pilot study to assess the efficacy of a 24-week topical treatment by latanoprost 0.1% on hair growth and pigmentation in healthy volunteers with androgenetic alopecia. J Am Acad Dermatol 2012; 66:794.</a></li><li><a class="nounderline abstract_t">Emer JJ, Stevenson ML, Markowitz O. Novel treatment of female-pattern androgenetic alopecia with injected bimatoprost 0.03% solution. J Drugs Dermatol 2011; 10:795.</a></li><li><a class="nounderline abstract_t">Suchonwanit P, Iamsumang W, Rojhirunsakool S. Efficacy of Topical Combination of 0.25% Finasteride and 3% Minoxidil Versus 3% Minoxidil Solution in Female Pattern Hair Loss: A Randomized, Double-Blind, Controlled Study. Am J Clin Dermatol 2019; 20:147.</a></li><li><a class="nounderline abstract_t">Olszewska M, Rudnicka L. Effective treatment of female androgenic alopecia with dutasteride. J Drugs Dermatol 2005; 4:637.</a></li><li><a class="nounderline abstract_t">Cusan L, Dupont A, Gomez JL, et al. Comparison of flutamide and spironolactone in the treatment of hirsutism: a randomized controlled trial. Fertil Steril 1994; 61:281.</a></li><li><a class="nounderline abstract_t">Paradisi R, Porcu E, Fabbri R, et al. Prospective cohort study on the effects and tolerability of flutamide in patients with female pattern hair loss. Ann Pharmacother 2011; 45:469.</a></li><li><a class="nounderline abstract_t">Yazdabadi A, Sinclair R. Treatment of female pattern hair loss with the androgen receptor antagonist flutamide. Australas J Dermatol 2011; 52:132.</a></li><li><a class="nounderline abstract_t">Mysore V. Mesotherapy in Management of Hairloss - Is it of Any Use? Int J Trichology 2010; 2:45.</a></li></ol></div><div id="topicVersionRevision">Topic 86648 Version 11.0</div></div>
<div class="row">
<div class="col-12">
<h4 style="text-align: center;padding: 20px;color: cadetblue;">References</h4>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/28396101" id="rid0" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>1 : The effectiveness of treatments for androgenetic alopecia: A systematic review and meta-analysis.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/27225981" id="rid1" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>2 : Interventions for female pattern hair loss.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/21700360" id="rid2" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>3 : A randomized, single-blind trial of 5% minoxidil foam once daily versus 2% minoxidil solution twice daily in the treatment of androgenetic alopecia in women.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/27391639" id="rid3" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>4 : A Phase III, Multicenter, Parallel-Design Clinical Trial to Compare the Efficacy and Safety of 5% Minoxidil Foam Versus Vehicle in Women With Female Pattern Hair Loss.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/15692478" id="rid4" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>5 : Evaluation and treatment of male and female pattern hair loss.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/14996087" id="rid5" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>6 : Minoxidil: mechanisms of action on hair growth.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/21980982" id="rid6" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>7 : Evidence-based (S3) guideline for the treatment of androgenetic alopecia in women and in men.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/20510769" id="rid7" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>8 : Innovative use of spironolactone as an antiandrogen in the treatment of female pattern hair loss.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/22171680" id="rid8" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>9 : Hair loss in women: medical and cosmetic approaches to increase scalp hair fullness.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/15787815" id="rid9" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>10 : Treatment of female pattern hair loss with oral antiandrogens.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/3155956" id="rid10" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>11 : Oral spironolactone therapy for female patients with acne, hirsutism or androgenic alopecia.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/19397563" id="rid11" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>12 : Successful treatment of female-pattern hair loss with spironolactone in a 9-year-old girl.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/17222303" id="rid12" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>13 : Treatment of female pattern hair loss with a combination of spironolactone and minoxidil.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/9497885" id="rid13" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>14 : Beneficial effect of spironolactone on androgenic alopecia.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/26369846" id="rid14" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>15 : Demographics of women with female pattern hair loss and the effectiveness of spironolactone therapy.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/32259535" id="rid15" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>16 : Spironolactone for treatment of female pattern hair loss.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/25796182" id="rid16" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>17 : Low Usefulness of Potassium Monitoring Among Healthy Young Women Taking Spironolactone for Acne.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/31360748" id="rid17" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>18 : Hyperkalemia in women with acne exposed to oral spironolactone: A retrospective study from the RADAR (Research on Adverse Drug Events and Reports) program.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/32446820" id="rid18" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>19 : Spironolactone use does not increase the risk of female breast cancer recurrence: A retrospective analysis.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/24189467" id="rid19" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>20 : Spironolactone use and the risk of breast and gynecologic cancers.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/27735065" id="rid20" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>21 : Spironolactone use and risk of incident cancers: a retrospective, matched cohort study.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/20442354" id="rid21" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>22 : Finasteride treatment of hair loss in women.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/30785992" id="rid22" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>23 : Female Pattern Hair Loss and Androgen Excess: A Report From the Multidisciplinary Androgen Excess and PCOS Committee.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/32184564" id="rid23" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>24 : Finasteride and Its Potential for the Treatment of Female Pattern Hair Loss: Evidence to Date.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/11050579" id="rid24" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>25 : Lack of efficacy of finasteride in postmenopausal women with androgenetic alopecia.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/16549704" id="rid25" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>26 : Finasteride treatment of female pattern hair loss.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/20569283" id="rid26" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>27 : 5 mg/day finasteride treatment for normoandrogenic Asian women with female pattern hair loss.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/15459533" id="rid27" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>28 : Finasteride treatment of patterned hair loss in normoandrogenic postmenopausal women.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/12524069" id="rid28" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>29 : Treatment of hyperandrogenic alopecia in women.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/12399766" id="rid29" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>30 : Hair loss in women with hyperandrogenism: four cases responding to finasteride.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/12399766" id="rid30" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>31 : Hair loss in women with hyperandrogenism: four cases responding to finasteride.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/12072067" id="rid31" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>32 : Effects of minoxidil 2% vs. cyproterone acetate treatment on female androgenetic alopecia: a controlled, 12-month randomized trial.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/2572103" id="rid32" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>33 : The effect of cyproterone acetate on hair roots and hair shaft diameter in androgenetic alopecia in females.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/1424176" id="rid33" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>34 : The importance of adequate serum ferritin levels during oral cyproterone acetate and ethinyl oestradiol treatment of diffuse androgen-dependent alopecia in women.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/32653577" id="rid34" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>35 : Evaluation of platelet-rich plasma as a treatment for androgenetic alopecia: A randomized controlled trial.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/30882509" id="rid35" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>36 : Platelet-Rich Plasma as a Treatment for Androgenetic Alopecia.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/28296142" id="rid36" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>37 : Platelet-rich plasma for androgenetic alopecia: Does it work? Evidence from meta analysis.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/27152474" id="rid37" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>38 : Meta-analysis of efficacy of platelet-rich plasma therapy for androgenetic alopecia.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/30141776" id="rid38" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>39 : Evaluating the Efficacy of Different Platelet-Rich Plasma Regimens for Management of Androgenetic Alopecia: A Single-Center, Blinded, Randomized Clinical Trial.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/29797431" id="rid39" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>40 : Efficacy of non-surgical treatments for androgenetic alopecia: a systematic review and network meta-analysis.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/32761771" id="rid40" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>41 : Platelet-rich plasma for androgenetic alopecia: Efficacy differences between men and women.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/27035501" id="rid41" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>42 : Randomized Placebo-Controlled, Double-Blind, Half-Head Study to Assess the Efficacy of Platelet-Rich Plasma on the Treatment of Androgenetic Alopecia.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/32649961" id="rid42" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>43 : The effect of platelet-rich plasma on female androgenetic alopecia: A randomized controlled trial.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/33088809" id="rid43" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>44 : Examining the Safety and Efficacy of Low-Level Laser Therapy for Male and Female Pattern Hair Loss: A Review of the Literature.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/24474647" id="rid44" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>45 : Efficacy and safety of a low-level laser device in the treatment of male and female pattern hair loss: a multicenter, randomized, sham device-controlled, double-blind study.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/19366270" id="rid45" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>46 : HairMax LaserComb laser phototherapy device in the treatment of male androgenetic alopecia: A randomized, double-blind, sham device-controlled, multicentre trial.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/30569416" id="rid46" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>47 : Low-level laser therapy for the treatment of androgenetic alopecia in Thai men and women: a 24-week, randomized, double-blind, sham device-controlled trial.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/30027912" id="rid47" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>48 : The effectiveness of adding low-level light therapy to minoxidil 5% solution in the treatment of patients with androgenetic alopecia.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/33068178" id="rid48" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>49 : Comparison of low-level light therapy and combination therapy of 5% minoxidil in the treatment of female pattern hair loss.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/31473295" id="rid49" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>50 : Minoxidil 1 mg oral versus minoxidil 5% topical solution for the treatment of female-pattern hair loss: A randomized clinical trial.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/29231239" id="rid50" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>51 : Female pattern hair loss: a pilot study investigating combination therapy with low-dose oral minoxidil and spironolactone.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/30246901" id="rid51" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>52 : Case series of oral minoxidil for androgenetic and traction alopecia: Tolerability&amp;the five C's of oral therapy.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/33333154" id="rid52" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>53 : Combination oral minoxidil and spironolactone for the treatment of androgenetic alopecia in adolescent girls.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/15135134" id="rid53" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>54 : The treatment of female pattern hair loss and other applications of surgical hair restoration in women.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/14576664" id="rid54" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>55 : Hair transplanting: an important but often forgotten treatment for female pattern hair loss.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/16616305" id="rid55" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>56 : Hair transplantation for men and women.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/15113284" id="rid56" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>57 : Medical and surgical therapies for alopecias in black women.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/21875758" id="rid57" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>58 : A randomized double-blind placebo-controlled pilot study to assess the efficacy of a 24-week topical treatment by latanoprost 0.1% on hair growth and pigmentation in healthy volunteers with androgenetic alopecia.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/21720663" id="rid58" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>59 : Novel treatment of female-pattern androgenetic alopecia with injected bimatoprost 0.03% solution.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/30206824" id="rid59" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>60 : Efficacy of Topical Combination of 0.25% Finasteride and 3% Minoxidil Versus 3% Minoxidil Solution in Female Pattern Hair Loss: A Randomized, Double-Blind, Controlled Study.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/16167423" id="rid60" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>61 : Effective treatment of female androgenic alopecia with dutasteride.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/8299783" id="rid61" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>62 : Comparison of flutamide and spironolactone in the treatment of hirsutism: a randomized controlled trial.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/21487083" id="rid62" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>63 : Prospective cohort study on the effects and tolerability of flutamide in patients with female pattern hair loss.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/21605098" id="rid63" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>64 : Treatment of female pattern hair loss with the androgen receptor antagonist flutamide.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/21188025" id="rid64" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>65 : Mesotherapy in Management of Hairloss - Is it of Any Use?</p>
</a>
</div>
</div>
</div>
</div>
</section>
</section>
<!-- End Main Menu Area -->
<!-- Start Search Popup Area -->
<!-- End Footer Area -->
<!-- Back to top -->
<a class="scrolltop" href="#top"><i class="icofont-hand-drawn-up"></i></a>
<!-- End Back to top -->
<!-- jQuery Min JS -->
<!-- Prpper JS -->
<!-- Bootstrap Min JS -->
<!-- Classy Nav Min Js -->
<!-- Owl Carousel Min Js -->
<!-- Magnific Popup JS -->
<!-- CounterUp JS -->
<!-- Waypoints JS -->
<!-- Form Validator Min JS -->
<!-- Contact Form Min JS -->
<!-- Main JS -->
<!-- Global site tag (gtag.js) - Google Analytics -->
</body>
</html>
